Artwork

Ozempic Wars | The Next Injection | 2

Business Wars

6,908 subscribers

published

iconShare
 
Manage episode 521278543 series 2007989
Content provided by Wondery. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Wondery or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Novo Nordisk can't keep up with demand for Ozempic and Wegovy, giving competitor Eli Lilly the edge in the GLP-1 market. And off-brand competitors continue to hammer the company's market position. Layoffs and board resignations signal that Novo Nordisk has entered a downward spiral. But with new leaders, acquisitions and deals, can they force a comeback?

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

  continue reading

789 episodes